UK markets open in 5 hours 7 minutes

Puma Biotechnology, Inc. (PBYI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
9.90+0.18 (+1.85%)
At close: 4:00PM EDT
9.90 0.00 (0.00%)
After hours: 04:55PM EDT
Sign in to post a message.
  • H
    Harry
    According to the 8 industry analysts covering Puma Biotechnology, the consensus is that breakeven is near. They anticipate the company to incur a final loss in 2021, before generating positive profits of US$4.2m in 2022. So, the company is predicted to
  • B
    Ballsio
    very good earnings report, plan on over $10/shr. before end of night
  • T
    Trader4Ever
    Why this is green when other bios are falling ....any news ?
  • B
    BBF
    should be above $12.
  • T
    Trader4Ever
    As a usual trend , down she goes 😒
  • H
    Harry
    I believe pbyi will return to profitability into 2022
  • Y
    Yahoo Finance Insights
    Puma Biotechnology is up 7.33% to 10.39
  • D
    Dude
    R revenues already beginning to decline and is neratinib the only asset
    ? Tyia
  • T
    Trader4Ever
    Why up 8 % without any news ?
    Anything happening ?
  • Y
    Yahoo Finance Insights
    Puma Biotechnology is up 7.70% to 10.21
  • m
    mahmoud
    Neratinib is an MST1 inhibitor and restores pancreatic β-cells in diabetes
    Amin Ardestani, Matthew S Tremblay, Weijun Shen, Kathrin Maedler
    Cell Death Discovery 5 (1), 1-3, 2019
    The failure of pancreatic insulin-producing β-cells is a central pathogenic hallmark of all forms of diabetes. Ninety-nine years after the discovery of insulin by Banting and Best, insulin is still the only available therapy for patients with diabetes once β-cell function is fully declined. We have not succeeded yet to establish a therapeutical intervention, which maintains and restores β-cell survival and function. Pathways and targets, which control stress response, cellular homeostasis, and the apoptosis network are consequently paralleled with tumor checkpoints and the risk to exploit them for the therapy of a chronic disease such as diabetes has so far outbalanced the promises of harnessing the power of an antiapoptotic strategy to target diabetes. At the cellular and organismal level, developmental, regenerative, antiapoptotic, as well as oncogenic pathways all share some common signaling hubs and regulatory networks. Thus, their deep understanding is absolutely required to safely target and monitor such pathways in the context of therapies. Decorated with multiple pattern recognition receptors, the pancreatic β-cell is highly sensitive to apoptotic stimuli. The necessity to survive periods of malnutrition and starvation during human evolution required highly regulated insulin secretion in tight adaptation to glucose and nutrient status. Now, overnutrition and physical inactivity fostered by Western diet and lifestyle abnormally alter glucose metabolism and energy homeostasis for which more and/or highly functional β-cells are needed to handle such metabolic imbalance. This progressive and constant high insulin demand from the β-cell leads to stress, β-cell overwork and exhaustion, degranulation, β-cell degeneration, and finally death resulting in progressive development of the relative insulin deficiency, unable to maintain normoglycemia and consequently to type 2 diabetes (T2D). Very similar in terms of consequences for the β-cell, β-cell death is thought to initiate and exacerbate immune-mediated type 1 diabetes (T1D), indicating the importance of β-cell loss in the process of T1D onset and progression.
    The identification of relevant molecular pathways and pathophysiological events that are responsible for β-cell demise in diabetes is instrumental for the better understanding of disease mechanisms and to ultimately address what is truly missing in diabetes: the β-cell. Through indepth studies of key elements of the apoptotic machinery, we have previously found serine/threonine kinase mammalian sterile 20-like kinase 1 (MST1), a core kinase of the Hippo developmental pathway, as a critical regulator of β-cell death and dysfunction in diabetes. Activated by multiple diabetogenic stimuli in human islets in vitro, in animal models of diabetes in vivo, as well as in pancreas sections obtained from patients with T2D, MST1 directly induces β-cell death and impairs insulin secretion 1 (Fig. 1). The importance of MST1 as a therapeutical target in diabetes has been confirmed at the level of the β-cell as well as for diabetic complications, ie, nephropathy and cardiomyopathy 2.
  • v
    valuegeek77
    I am flabbergasted why this is even down pre-market. Granted they dont have next blockbuster, but we are talking about under 600 million company. They have stabilized sales at 250 million run rate, have several catalysts this year, they are cash flow neutral with 111 million cash, chance of windfall $ from patent dispute, M&A possibility etc.
  • H
    Henry
    https://finance.yahoo.com/quote/PBYI/insider-transactions?p=PBYI
    CEO sells shares at $12.78. Yes, PBYI will go under 8 for sure.
    Get the latest insider transactions for Puma Biotechnology Inc (PBYI). Find out the total of insider shares held, purchased and sold.
    Get the latest insider transactions for Puma Biotechnology Inc (PBYI). Find out the total of insider shares held, purchased and sold.
    finance.yahoo.com
  • $
    $
  • M
    MAQ
    A buyout could be a possibility??, the way PBYI is holding today shows the stock will go up or a buyout could happen. No doubt China is a big market sales will go up looks cheap at this level.
  • V
    Vs
    As usual market converting good news to bad for underperforming stock and bad to good for outperforming stock.

    They generate adjusted profit, net cash flow, grow q over q , beat revenue target and addressing side effect concerns without overspending on marketing and yet market look at as there is no future.
  • Y
    Yahoo Lover
    Since they got expansion label approval last month or so, it will help on the revenue.
  • B
    Bechody
    This is the market is where strong gets stronger and weak gets weaker. PBYI will be dissolved
  • V
    Vs
    $CLVS and $PBYI board need to actively look for buyer. Their stock price so low with promising drug that they likely have significant interest.
  • Z
    Zahir
    There seems to be little to no interest in this stock. what did I miss